Results 21 to 30 of about 8,230,812 (271)

Polygenic Prediction of Peripheral Artery Disease and Major Adverse Limb Events. [PDF]

JAMA Cardiol
ImportancePeripheral artery disease (PAD) is a heritable atherosclerotic condition associated with functional decline and high risk for limb loss. With growing knowledge of the genetic basis for PAD and related risk factors, there is potential opportunity to identify individuals at high risk using polygenic risk scores (PRSs).ObjectiveTo develop a ...
Flores AM, Ruan Y, Misra A, Cho SMJ, Selvaraj MS, Bellomo TR, Nakao T, Rosenfield K, Eagleton M, Hornsby W, Patel AP, Natarajan P.   +11 more
europepmc   +3 more sources

Monocyte Count as a Predictor of Major Adverse Limb Events in Aortoiliac Revascularization. [PDF]

J Clin Med
Background/Objectives: Atherosclerosis is a leading cause of death, especially in the developed world, and is marked by chronic arterial inflammation and lipid accumulation. As key players in its progression, monocytes contribute to plaque formation, inflammation, and tissue repair.
Pereira-Neves A, Dias L, Fragão-Marques M, Vidoedo J, Ribeiro H, Andrade JP, Rocha-Neves J.   +6 more
europepmc   +3 more sources

Major Adverse Events in Patients with Peripheral Artery Disease after Endovascular Revascularization: A Retrospective Study [PDF]

, 2022
Objective: For peripheral artery disease (PAD) patients, after endovascular revascularization, it is crucial to manage associated factors that can affect the risk of major adverse events.
최모나, 고영국, Yong Sook Yang, Young-Guk Ko, Mona Choi, Mihui Kim, Ko, Young-Guk, Yang, Yong Sook, Choi, Mona, Kim, Mihui   +9 more
core   +2 more sources

Major adverse limb events and major adverse cardiac events after contemporary lower extremity bypass and infrainguinal endovascular intervention in patients with claudication. [PDF]

J Vasc Surg, 2018
Major adverse limb events (MALEs) and major adverse cardiovascular events (MACEs) at 30 days provide standardized metrics for comparison and have been adopted by the Society for Vascular Surgery's objective performance goals for critical limb ischemia.
Fashandi AZ, Mehaffey JH, Hawkins RB, Kron IL, Upchurch GR, Robinson WP.   +5 more
europepmc   +4 more sources

Impact of geriatric nutritional risk index on prognosis in peripheral artery disease patients undergoing endovascular therapy

The Journal of Clinical Hypertension, 2023
The prevalence of peripheral artery disease continues to rise, with major amputations and mortality remaining prominent. Frailty is a significant risk factor for adverse outcomes in the management of the vascular disease.
Dikang Pan, Jiabin Wang, Julong Guo, Zhixiang Su, Jingyu Wang, Jianming Guo, Xiaoming Shi, Yongquan Gu   +7 more
doaj   +1 more source

Antithrombotic therapy in peripheral arterial disease

Frontiers in Cardiovascular Medicine, 2022
BackgroundPatients with peripheral arterial disease (PAD) are at increased risk for major adverse cardiovascular events (MACE) such as cardiovascular death, myocardial infarction, and stroke as well as major adverse limb events (MALE) such as amputation ...
Christine Espinola-Klein, Gerhard Weißer, Volker Schmitt, Volker Schmitt, Melanie Schwaderlapp, Thomas Munzel   +5 more
doaj   +1 more source

Urinary Cystatin C Has Prognostic Value in Peripheral Artery Disease

Biomolecules, 2022
Despite its association with adverse outcomes, peripheral artery disease (PAD) remains undertreated. Cystatin C is elevated in patients with renal disease and may be a marker of cardiovascular disease.
Ben Li, Abdelrahman Zamzam, Muzammil H. Syed, Niousha Jahanpour, Shubha Jain, Rawand Abdin, Mohammad Qadura   +6 more
doaj   +1 more source

Development of a biomarker panel for assessing cardiovascular risk in diabetic patients with chronic limb-threatening ischemia (CLTI): a prospective study

Cardiovascular Diabetology, 2023
Background Lower-extremity endovascular revascularization (LER) is often required for diabetic patients with chronic limb threatening ischemia (CLTI). During the post-revascularization period patients may unpredictably experience major adverse cardiac ...
Elisabetta Nardella, Federico Biscetti, Maria Margherita Rando, Andrea Leonardo Cecchini, Maria Anna Nicolazzi, Enrica Rossini, Flavia Angelini, Roberto Iezzi, Luis H. Eraso, Paul J. Dimuzio, Dario Pitocco, Massimo Massetti, Antonio Gasbarrini, Andrea Flex   +13 more
doaj   +1 more source

Sex-Specific Risks of Major Cardiovascular and Limb Events in Patients With Symptomatic Peripheral Artery Disease. [PDF]

, 2020
BACKGROUND Patients with peripheral artery disease (PAD) have a higher risk of major adverse cardiovascular events (MACE) compared with those without PAD.
Rockhold, Frank W., Blomster, Juuso I., Rockhold, Frank W, Baumgartner, Iris, Katona, Brian G, Hiatt, William R, Hess, Connie N, Hess, Connie N., Mahaffey, Kenneth W, Jones, W. Schuyler, Kavanagh, Sarah, Fowkes, F. Gerry R., Patel, Manesh R., Blomster, Juuso I, Berger, Jeffrey S, Patel, Manesh R, Mahaffey, Kenneth W., Jones, W Schuyler, Hiatt, William R., Berger, Jeffrey S., Katona, Brian G., Haine, Axel, Norgren, Lars, Fowkes, F Gerry R   +23 more
core   +2 more sources

Mono or Dual Antiplatelet Therapy for Treating Patients with Peripheral Artery Disease after Lower Extremity Revascularization: A Systematic Review and Meta-Analysis

Pharmaceuticals, 2022
The efficacy of dual antiplatelet therapy (DAPT) for patients with peripheral artery disease (PAD) after lower-limb intervention remains controversial. Currently, the prescription of DAPT after an intervention is not fully recommended in guidelines due ...
Shang-Yu Tsai, Ying-Sheng Li, Che-Hsiung Lee, Shion-Wei Cha, Yao-Chang Wang, Ta-Wei Su, Sheng-Yueh Yu, Chi-Hsiao Yeh   +7 more
doaj   +1 more source